Genomic Health Inc. (NASDAQ:GHDX)’s share price dropped 1.4% during trading on Tuesday . The company traded as low as $26.76 and last traded at $27.10, with a volume of 269,364 shares traded. The stock had previously closed at $27.48.

GHDX has been the topic of a number of research reports. Leerink Swann reaffirmed a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Canaccord Genuity raised shares of Genomic Health from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Wednesday, June 1st. Jefferies Group raised their target price on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th. Finally, Bank of America Corp. set a $28.00 target price on shares of Genomic Health and gave the stock a “sell” rating in a research report on Wednesday, August 3rd. Three research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. Genomic Health has an average rating of “Hold” and a consensus target price of $32.44.

The stock’s 50-day moving average is $28.02 and its 200 day moving average is $26.58. The firm’s market cap is $898.67 million.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). The firm earned $81.97 million during the quarter, compared to analyst estimates of $81.27 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. The business’s revenue for the quarter was up 16.1% compared to the same quarter last year. On average, equities research analysts predict that Genomic Health Inc. will post ($0.47) EPS for the current year.

In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $28.87, for a total value of $144,350.00. Following the transaction, the chief operating officer now directly owns 40,426 shares in the company, valued at approximately $1,167,098.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Felix Baker bought 100,000 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was purchased at an average price of $27.02 per share, for a total transaction of $2,702,000.00. The disclosure for this purchase can be found here.

A number of institutional investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. raised its position in Genomic Health by 29.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 60,100 shares of the company’s stock valued at $2,116,000 after buying an additional 13,600 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Genomic Health by 16.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 65,765 shares of the company’s stock valued at $2,315,000 after buying an additional 9,308 shares in the last quarter. Finally, Royce & Associates LLC raised its position in shares of Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock valued at $2,341,000 after buying an additional 31,500 shares in the last quarter.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.